Press

ImpriMed
in the news

For press opportunities, please email press@imprimedicine.com.

A girl kissing her dog, a west highland white terrier, with closed eyes

In the News

May 26, 2022

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

Read More
One Million by One Million Blog
May 25, 2022

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

Read More
One Million by One Million Blog
May 24, 2022

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

Read More
One Million by One Million Blog
April 23, 2022

Novel veterinary oncologic treatments and diagnostics

Read More
dvm360 logo
February 15, 2022

AI’s Computing Power Could Make Fusion Energy Practical

Read More
Lifewire Tech for Human Logo
December 26, 2021

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Read More
Startup to follow logo
September 23, 2021

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

Read More
IdeaMensch logo
May 30, 2021

This Test Might Make All The Difference When Fighting Lymphoma

Read More
Canine Cancer Alliance Logo
April 6, 2021

ImpriMed: Fighting Cancer — From Dogs To Humans

Read More
Startup Thread Logo
September 4, 2017

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

Read More
TechCrunch Logo

Video & Podcast Interviews

January 13, 2022

Personalized Medicine in Veterinary Oncology

Veterinary Innovation Podcast
Watch or Listen Now→
August 10, 2021

Interview with Dr. Sungwon Lim, CEO of ImpriMed

Innovating with Scott Amyx
Watch or Listen Now→
July 13, 2021

Tech Founder Interview with Sungwon Lim, CEO & Founder of ImpriMed

Tech Founder Show by Insivia
Watch or Listen Now→
November 12, 2020

Which Drugs Can Kill Your Dog's Cancer Cells? - ImpriMed's Sungwon Lim | Canine Cancer Rebel

Canine Cancer Alliance
Watch or Listen Now→
November 28, 2019

Interview with Sungwon Lim: Founder & CEO of ImpriMed

Entrepreneurship, Interviews, Level Up!
Watch or Listen Now→

Press Releases

June 13, 2022

40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder

Read More →
May 2, 2022

ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference

Read More →
March 21, 2022

ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes

Read More →
February 16, 2022

ImpriMed Publishes Exclusive Canine Patients Data Analysis

Read More →
February 1, 2022

ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice

Read More →
January 24, 2022

ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion

Read More →
October 19, 2021

ImpriMed Launches New Diagnostic Services for Canine Lymphoma

Read More →
July 12, 2021

ImpriMed Initiates Feline Lymphoma Drug Response Prediction Study

Read More →
May 24, 2021

ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma

Read More →
April 13, 2021

ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market

Read More →
February 2, 2021

ImpriMed Launches Advanced Precision Medicine Service for Canine Blood Cancers

Read More →
April 12, 2019

ImpriMed Raises $4M for Customized Cancer Treatments for Dogs

Read More →